SBPH - Spring Bank Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.12
+0.02 (+0.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.10
Open5.09
Bid5.12 x 1200
Ask5.15 x 800
Day's Range4.97 - 5.33
52 Week Range3.58 - 15.00
Volume38,500
Avg. Volume98,160
Market Cap84.189M
Beta (3Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-1.83
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.92
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into a research agreement with The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to evaluate Spring Bank’s hepatitis B virus (HBV) antisense oligonucleotide compounds. Spring Bank has entered into a non‐clinical evaluation agreement to access NIAID’s preclinical services program to further evaluate Spring Bank’s HBV antisense oligonucleotide compounds.

  • GlobeNewswire10 days ago

    Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Pamela Klein, M.D., has been elected as an independent member of its Board of Directors. “We are thrilled to welcome Dr. Klein to our Board of Directors,” said Scott Smith, chair of the Board of Directors of Spring Bank.

  • GlobeNewswire19 days ago

    Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the company’s intravenously (IV)-administered STimulator of INterferon Gene (STING) agonist development candidate, SB 11285, to initiate a Phase 1 trial with the principal goals of evaluating safety, tolerability and initial anti-tumor activity in patients with advanced solid tumors. Upon receipt of regulatory clearance, the company anticipates enrolling patients in this trial with a plan to report top-line results in mid-2020.

  • GlobeNewswire23 days ago

    Spring Bank to Present Pre-Clinical Data on Its Novel STING Antagonist Program at The Autoimmunity Conference

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present for the first time pre-clinical data from its STimulator of INterferon Genes (STING) antagonist program at The Autoimmunity Conference organized by the Federation of American Societies for Experimental Biology (FASEB) in Pacific Grove, California, from July 7-12, 2019. “Aberrant activation of the STING pathway is believed to cause certain autoimmune and inflammatory diseases, including Systemic Lupus Erythematosus (SLE), Aicardi–Goutières Syndrome, Sjögren’s syndrome and certain other rare diseases,” commented Dr. Kris Iyer, co-founder and Chief Scientific Officer of Spring Bank Pharmaceuticals.

  • GlobeNewswirelast month

    Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it would present promising results from a healthy volunteer study highlighting the activation of the immune system with inarigivir soproxil 400mg, an orally administered hepato-selective immunomodulator, at The Science of HBV Cure 2019 meeting in Singapore on Saturday, June 8, 2019. The results from this study further demonstrate that inarigivir could become a backbone immune-activator in a combinatorial treatment for chronic hepatitis B virus (HBV) that accelerates and substantially increases functional cure rates for chronic HBV patients.

  • GlobeNewswire2 months ago

    Spring Bank Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference

    HOPKINTON, Mass., May 28, 2019 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.

  • Did Changing Sentiment Drive Spring Bank Pharmaceuticals's (NASDAQ:SBPH) Share Price Down By 50%?
    Simply Wall St.2 months ago

    Did Changing Sentiment Drive Spring Bank Pharmaceuticals's (NASDAQ:SBPH) Share Price Down By 50%?

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...

  • GlobeNewswire3 months ago

    Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update

    ACHIEVE trial completed – inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profilePhase 2 co-administration study of inarigivir +.

  • GlobeNewswire3 months ago

    Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced at The International Liver Congress™ (ILC), the 2019 Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, robust results from the recently completed inarigivir Phase 2 dose escalation ACHIEVE trial for patients with chronic hepatitis B virus (HBV). Spring Bank is developing inarigivir, an orally-administered hepatic-selective immunomodulator, as a potential backbone in a combinatorial treatment for chronic HBV with the goal to accelerate and substantially increase chronic HBV functional cure rates in a simple, safe and selective manner.

  • GlobeNewswire3 months ago

    Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)

    HOPKINTON, Mass., April 10, 2019 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.

  • GlobeNewswire4 months ago

    Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced the acceptance of a late breaker oral presentation and a poster presentation at The International Liver Congress™ (ICL), the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14, 2019. The late-breaker oral presentation by Professor Man-Fung Yuen, Chief of Gastroenterology and Hepatology, University of Hong Kong, and Principal Investigator of the ACHIEVE trial, scheduled for General Session II and Award Ceremony I, will describe the final top-line results from all inarigivir (IRIG) ACHIEVE trial cohorts, including the 200mg dosing cohort.

  • GlobeNewswire4 months ago

    Spring Bank Pharmaceuticals to Participate in Jefferies 2019 HBV Summit

    HOPKINTON, Mass., March 14, 2019 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of SBPH earnings conference call or presentation 11-Mar-19 12:00pm GMT

    Q4 2018 Spring Bank Pharmaceuticals Inc Earnings Call

  • GlobeNewswire4 months ago

    Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights

    Conference Call to be Held at 8:00 am Eastern TimeInarigivir Late-Breaker Abstract Accepted for Oral Presentation at EASL The International Liver Congress 2019 HOPKINTON,.

  • ACCESSWIRE4 months ago

    Spring Bank Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 11, 2019 / Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 11, 2019 ...

  • GlobeNewswire5 months ago

    Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11

    HOPKINTON, Mass., March 04, 2019 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.

  • GlobeNewswire5 months ago

    Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced the appointment of Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development. “We are thrilled to have Atif, an innovative and experienced developer of novel oncology and immunology compounds, join Spring Bank to lead our oncology and immunology clinical development team,” said Martin Driscoll, president and chief executive officer of Spring Bank.

  • GlobeNewswire7 months ago

    Spring Bank Pharmaceuticals Appoints Scott Smith as Chairman of the Board

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it has appointed successful biopharmaceutical industry leader and veteran Scott Smith as Chairman of the Board, effective January 1, 2019. Mr. Smith will replace Martin Driscoll, Spring Bank’s President and Chief Executive Officer, as Chairman of the Board.  Mr. Driscoll will continue to serve as a member of the Board and as President and Chief Executive Officer of the company.

  • GlobeNewswire7 months ago

    Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics

    Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, will host a research and development day today in New York to discuss its expanding pipeline of novel small molecule nucleotides that leverage the Company’s proprietary development capabilities. The R&D Day will include presentations by Dr. Ira Jacobson, Director of Hepatology at NYU Langone Center, Dr. Adam J. Gehring, Biology Lead at Toronto General Hospital Research Institute (TGHRI), and Dr. Jason Luke, Assistant Professor of Medicine, University of Chicago, specializing in cancer immunotherapy biomarker and drug development for solid tumors.

  • GlobeNewswire8 months ago

    Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy

    Spring Bank is developing multiple second-generation STING agonist compounds that are designed to activate the innate and adaptive immune systems.  Spring Bank believes that its STING agonists are best-in-class agents and are differentiated due to their potential to be administered either intravenously (IV) or intratumorally (IT) for potent and durable anti-tumor activity in multiple cancer models.  Spring Bank’s STING agonists also have the potential to be used in combination with other therapeutic modalities to enhance efficacy. Subject to completion of IND-enabling studies, Spring Bank plans to initiate clinical trials for SB 11285 in 2019.  SB 11285 could be the first IV administered STING agonist to enter clinical development.

  • GlobeNewswire8 months ago

    Spring Bank Announces Additional Inarigivir Results at AASLD Conference

    In the poster of distinction presentation titled Inarigivir is a Novel Selective Inhibitor of the HBV Replicase Complex In Vitro, Professor Stephen Locarnini, Head of Research & Molecular Development at the Victorian Infectious Diseases Reference Laboratory and Principal Investigator of the Virology Core for the ACHIEVE trial, will present data on the direct acting anti-viral (DAA) effect of inarigivir on HBV viral replication. In vitro studies in HBV cell culture systems have demonstrated that inarigivir has the ability to prevent viral replication by inhibiting HBV replication at the level of reverse transcription and/or blocking priming or subsequent primer translocation within the viral nucleocapsid, which appears independent of the RIG-I mediated activation of IRF-3 and cytokine activation.

  • GlobeNewswire8 months ago

    Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences

    HOPKINTON, Mass., Nov. 05, 2018 -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.

  • GlobeNewswire9 months ago

    Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy

    Spring Bank is developing multiple next-generation STING agonist compounds that are designed to activate the innate and adaptive immune systems. Spring Bank believes that its lead STING agonist development compound, SB 11285, could be used to treat multiple tumor types and has the potential to be used in combination with other therapeutic modalities to enhance efficacy.